ACADIA 制药公司CFO和COO销售了大量股份,尽管Q3的预期收入将下降。 ACADIA Pharmaceuticals' CFO and COO sold significant shares, despite Q3 earnings beating expectations.

ACADIA制药公司CFO和COO已经出售股票,其股票所有权分别减少了16.14%和14.26%。 ACADIA Pharmaceuticals CFO and COO have sold shares, reducing their stock ownership by 16.14% and 14.26%, respectively. 股票于11月19日下跌8.82美元,降至16.21美元,市场上限为27亿美元。 The stock dropped $0.82 on November 19th to $16.21, with a market cap of $2.70 billion. 据该公司报告,Q3收入为每股0.20美元,超过预期,收入增加18.3%,达到2.540亿美元。 The company reported Q3 earnings of $0.20 per share, surpassing expectations, with revenue up 18.3% to $250.40 million. 分析员有一个“机动购买”共识,平均价格目标是25.56美元。 Analysts have a "Moderate Buy" consensus with a $25.56 average price target.